# Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application

> **NCT00436527** · PHASE4 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 26 (actual)

## Conditions studied

- Rosacea

## Interventions

- **DRUG:** Metronidazole gel 1%

## Key facts

- **NCT ID:** NCT00436527
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2022-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00436527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00436527, "Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00436527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*